Gefitinib and rapamycin synergistically inhibit advanced human NSCLC cell line (H1975, harboring EGFR T790M secondary mutation) proliferation and tumor formation by upregulating cell autophagy activities, thereby inducing cell autophagy–EGFR positive feedback regulation. The gene discussed is EGFR; the disease is neoplasm.